Key takeawayInsulet’s third-quarter profit surge was driven mainly by margin improvement, but slower overseas growth and weaker benefits from pricing mix, alongside intensifying competition, led management to repeatedly lower its growth outlook for 2027; Bernstein, meanwhile, raised its price target as it lowered its sales estimates, citing a higher valuation multiple.
Why did profit beat expectations by more than revenue in the third quarter?
- Insulet’s third-quarter revenue was 842 million dollars, up 19.6% year over year on a constant-currency basis and 1.2% above the consensus estimate of 832 million dollars; adjusted earnings per share were 1.99 dollars, up 60% and 25.6% above the consensus estimate of 1.59 dollars.
- Revenue performance was driven mainly by overseas business: overseas Omnipod sales grew 33% year over year, 3.6% above consensus; U.S. sales grew 14.7%, broadly in line with consensus. About half of the overseas revenue beat came from inventory adjustments in France and Canada, totaling approximately 5 million dollars.
- Profit growth outpaced revenue growth, reflecting support from both gross margin and expenses: adjusted gross margin increased by 200 basis points year over year to 74.2%, which the company attributed to improved manufacturing efficiency; adjusted operating margin rose by 490 basis points to 22.0%, also benefiting from lower employee bonus accruals.
Why was the growth starting point for 2027 lowered despite the quarterly beat?
- Management raised some of its 2026 guidance: the full-year constant-currency revenue growth range was narrowed to 21%–22% from 20%–22%; the overseas Omnipod growth outlook increased to 32%–33%, while the U.S. range was 17.5%–18.5%, with its midpoint unchanged. The expected expansion in adjusted operating margin was raised from about 100 basis points to about 150 basis points.
- However, management lowered its overall company growth outlook for 2027 to slightly below the mid-teens, below the previously stated mid-teens growth framework; U.S. growth is expected to come in at the low end of the previous 9%–14% range. Overseas markets also face tougher comparisons following launches in key countries and weaker pricing-mix benefits from Omnipod 5 conversions; the company expects about 80% of overseas customers to have completed the conversion by the end of 2026.
How can Insulet sustain growth as competition intensifies?
- New competitors entering the market will put pressure on Insulet’s share of new customers: U.S. new-customer starts were flat in the third quarter, while global new-customer starts grew only in the low single digits; over the same period, the global user base grew by more than 20%, and U.S. business growth came more from expansion among existing users. Management expects its share of new customers to decline by a few percentage points, but still expects to lead in new-customer starts.
- Management’s growth thesis is that more competitors could also expand the automated insulin delivery (AID) category, while there is still room for patients to switch from multiple daily injections (MDI) to pump therapy. The company says AID penetration among U.S. patients with type 1 and type 2 diabetes, and among overseas patients with type 1 diabetes, is below that of continuous glucose monitoring (CGM).
- Improved retention and new products could provide support over time, but their near-term contribution is limited: the company said retention among users with type 2 diabetes improved in the third quarter, but did not quantify the change; Omnipod 6 remains scheduled to launch in 2027, while management’s preliminary 2027 outlook includes only a limited contribution from new products.
Why did Bernstein lower its sales estimates but raise its price target?
- Bernstein maintained its Outperform rating and raised its price target from 175 dollars to 200 dollars; at the same time, it lowered its forward sales estimate used for valuation from 4.11 billion dollars to 4.01 billion dollars. The price-target increase did not reflect higher sales expectations, but rather an increase in its price-to-sales valuation multiple from 3.0x to 3.5x; the report attributed this to an improvement in valuation multiples across medical technology.